4 October 06
PROGEN CHANGES ITS NASDAQ TICKER SYMBOL TO PGLA

Brisbane, Australia. 4 October 2006. Progen Industries (ASX: PGL, NASDAQ: PGLAF), a global developer of anti-cancer drugs, today announced a change in its NASDAQ Capital Market ticker symbol from PGLAF to PGLA.

The change is effective from 9 October 2006.

About Progen: Progen Industries Limited is an Australian based globally focused biotechnology company committed to the discovery, development and commercialisation of small molecule pharmaceuticals for the treatment of cancer and other serious diseases.

Progen's three key areas of focus are:

  • Clinical Development - via a focused clinical trial program involving its two compounds PI-88 and PI-166.
  • Drug Discovery - projects focusing on the development of potent, selective inhibitors of carbohydrate-protein interactions, which are implicated in many disease processes.
  • Manufacturing Services – PI-88 manufacturing and supply for the clinical program and contract biological process development, manufacture and quality assurance services.

Keywords - Progen, cancer, NASDAQ

 

Web links to selected recent news and other information about Progen:

Progen's Financial Year ends with a positive outlook for 2007 www.progen.com.au/?page=nepress2006.html

Progen prepares for accelerated clinical development

 www.progen.com.au/?page=nepress2006.html
Progen meets with FDA www.progen.com.au/?page=nepress2006.html
New CEO to lead Progen though next stages of cancer drug development www.progen.com.au/?page=nepress2005.html
Open Briefing: New Trial & Update www.progen.com.au/?page=nepress2005.html
AUSIndustry Grant offered ($3.4m) www.progen.com.au/?page=nepress2005.html
PI-88 mode of action www.progen.com.au/?page=nepress2005.html
Progen's drug development pipeline www.progen.com.au/?page=pihome.html
Progen Industries Ltd www.progen.com.au